DonCorleone77 Posted - 9 hours ago

$SNY Sanofi seeking initial bids for $20B consumer health unit, Bloomberg reports Sanofi is seeking initial bids for its $20B consumer health arm as the company moves ahead with preparations for a potential listing of the arm, Bloomberg's Pamela Barbaglia, Dinesh Nair, Francesca Veronesi, and Swetha Gopinath report. The drugmaker has asked potential suitors to make first-round bids by mid-July, according to people familiar with the matter. Advent International and France's PAI Partners are seen as the most keen on the asset, the people say.

aprit Posted - 1 day ago

$NVAX Just buy $SNY

fda_tracker Posted - 1 day ago

$SNY New PDUFA Date 2025-03-28 Sanofi - Aventis Groupe Link:https://www.globenewswire.com/news-release/2024/06/21/2902104/0/en/Press-Release-ISTH-Sanofi-advances-leadership-in-hemophilia-with-new-data-for-ALTUVIIIO-and-fitusiran.html Calendar:http://www.fdatracker.com/fda-calendar/

clan Posted - 2 days ago

@ItzaFugazi @Spottswoode $MNKD $NVO $SNY $LLY EVERYONE should watch the first 17 mins of this linked video!!! Made me tingle down in my nether region. https://www.hcplive.com/view/diabetes-dialogue-inhale-3-and-diabetes-tech-updates-with-grazia-aleppo-md

Aigner_Andreas Posted - 4 days ago

TD BUY $SNY at 46.85, Supp 46.25 Resis 49.51 R7 HiLo 31% T1Y 60 strong_buy 1.2 DIV 4.23% #Sanofi ADR #stocks #trading #finance #market

Traderdogzz21 Posted - 5 days ago

$SNY $AGBA BUY THE SQUEEZE

ajbski Posted - 5 days ago

@chith84 $NVAX With a market cap of $119B, Sanofi has leveled the playground. $NVAX is going to fly. $SNY

peugout505 Posted - 5 days ago

@STCG great post, thank you. Holding 42k shares at $4.65 avg since 2020. Bought the entire way up and down. $DRIO shouldn't have IPO'd as it has zero revenue traction. We're obviously early. Contract after contract / partnership announcements without ANY revenue performance, minus crumbs + BS research "partnerships", masked as marketing validation for $SNY. CRO just swapped out, goalposts moved. While thesis sounds strong: software/hardware/consumer flywheel of data to improve conditions - business is UNPROVEN. Anyone have clear path to revenue to share? Seriously- chart is a path to $5 share price. I'm close to dumping it all to buy $ZVRA on the run up to FDA approval in Sept...

RolandRickPerry Posted - 5 days ago

$GOVX Link to our 9-page report below. In our opinion, GeoVax is now on the radar of every vaccine maker like Pfizer $PFE, Moderna $MRNA, Novavax $NVAX , and Sanofi $SNY who have billions to invest, and assist start-ups finish clinical trials. https://internetstockreview.com/nine-page-summary-report-on-geovax-govx/

STCG Posted - 6 days ago

$DRIO Not that anyone cares, but here is where I sit on DRIO. The company Acquires Upright for 31M, Acquires twill for 30M, Acquires AI enables PHYsimax for a few Million. gets 30M partnership revenue from $SNY, Expanding SNY partnership (lets see that PR already!). Multiple large partnerships with the blues and other health plans (Aetna). Twil investors invested like 100M+ into Twil and are wanting this to work out so they can get a return on their original Twil investment. DRIO is 20X a better company than they were 5 years ago and the price is 1/20th what it was before all these improvements. Twil helped with revenue. Now need closer to break even. Market cap is only 33M or so? Seems low. But they will need to paint a picture of their runway to cash flow positive. My average is around $1.57 right now. PT is $3.0 to start selling some shares. Holding some for a much higher price target. Not buying more until there is a clear inflection point that the market recognizes.

BTC321 Posted - 1 week ago

$NVAX $SNY SANOFI IS FROM FRANCE! THANK GOD THEY HAVE NOVAVAX AS PARTNER! https://www.connexionfrance.com/news/why-covid-19-hospital-cases-are-rising-again-in-france/665273

briefingcom Posted - 1 week ago

$SNY: Sanofi: Belharra Therapeutics announced a strategic collaboration with Sanofi to advance the discovery of novel small molecule therapeutics for immunological diseases https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240618070725SNY&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

forloveoflemons Posted - 1 week ago

$SNY as an MS patient I am buying in on this stock primarily because of the potential of their phase 3 CD40L drug called Frexalimab (SAR441344) for MS. Phase 2 was a huge success and innovative. As the first second-generation anti-CD40L antibody to show efficacy in MS, frexalimab is thought to block the costimulatory CD40/CD40L cellular pathway necessary for adaptive (T and B cells) and innate (macrophages and dendritic cells) immune cell activation and function, without lymphocyte-depletion. Sanofi is developing SAR441344 under an exclusive license from ImmuNext Inc.

DonCorleone77 Posted - 1 week ago

$IPHA $SNY Innate Pharma announces updated results from SAR443579/IPH6101 Innate Pharma (IPHA) announced that updated efficacy and safety results from the dose-escalation part of the Phase 1/2 study with SAR443579/IPH6101, an investigational CD123 targeting NKp46/CD16-based Natural Killer Cell Engager, or NKCE, from a joint research collaboration between Innate Pharma and Sanofi (SNY) and Anket platform lead asset, were shared in an oral presentation at the European Hematology Association 2024 Congress in Madrid, Spain on Sunday. The study, led by Sanofi, tests SAR'579 as a monotherapy for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia and high-risk myelodysplasia. SAR'579 has FDA Fast Track Designation for the treatment of acute myeloid leukemia. Fifty-nine patients across 11 dose levels were treated. Patients had received a median of 2 prior lines of treatment. A maximum response rate was observed at a final target dose of 1 mg/kg every week with 5 AML patients achieving a CR. The median treatment duration was 7.9 weeks, with durable CR observed in 3 patients with 2 remaining on maintenance therapy as of the data cutoff. SAR'579 was well tolerated up to doses of 6 mg/kg every week. These data will form the basis for selection of recommended doses for development in the Phase 2 portion of the trial.

ajbski Posted - 1 week ago

$NVAX Not surprised that the FDA moved the goalposts for $PFE $MRNA. The mRNA vax mafia has a very large “political donation” lobby. Still very bullish on NVAX; $SNY partnership is huge.

Lazarus2024 Posted - 1 week ago

@DonCorleone77 Do they have the superior M-matrix adjuvant? No, $nvax and $SNY have that.

frontiere Posted - 1 week ago

$NVAX $SNY Novavax ref=$16.73 with great Vol come great RV option arb opps… Took profits yesterday in a -2xJul/+Oct 12.5p structure from entry=-$5 (for credit) to exit=$75. Reader can make their own judgement as to the trade thesis. Still net long via other structures.

iatsebob Posted - 1 week ago

$NVAX this is exactly my point. Few stocks go up 10x overnight. This price discovery will likely take months. The important thing to remember is that this company has emerged from the depths and is now ascending the industry with one of the biggest players out there, $SNY I’m not scared. Let the traders trade. I’ve invested and am ready to wait for the long term capital gains treatment. Who’s with me??

iatsebob Posted - 1 week ago

$NVAX volume is low and I’m sure big $$$ is doing their DD to make sure this $SNY deal is for real. Sadly, this company is suffering from the once bit, twice shy syndrome. I’m betting that this latest deal is the beginning of a meaningful turnaround. There is no other reason for Sanofi to get involved the way they did unless the value is there.

GeoWhite Posted - 1 week ago

$SNY write a check for $NVAX already

ajbski Posted - 1 week ago

$NVAX 🚀🚀🚀 “(Novavax’s) Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection” Front. Immunol., 22 November 2021 $XBI $IBB $SNY https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.747774/full

DonCorleone77 Posted - 2 weeks ago

$REGN $SNY Regeneron, Sanofi announce FDA approved Kevzara for treatment of pJIA Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Kevzara for the treatment of patients weighing 63 kg or greater with active polyarticular juvenile idiopathic arthritis, pJIA,, a form of arthritis that impacts multiple joints at a time. "Polyarticular juvenile idiopathic arthritis can be a painful disease for children where multiple joints are impacted by this chronic infammation," said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. "Not only are their daily lives impacted, but their futures can be disrupted without adequate treatment. The approval of Kevzara in polyarticular juvenile idiopathic arthritis provides these vulnerable patients and their families a new FDA-approved treatment option to help navigate this disease."

DonCorleone77 Posted - 2 weeks ago

$GSK $PFE $SNY GSK starts process for appeal of recent Delaware Daubert ruling GSK (GSK) confirms that the company has taken the first step to seek appeal of the recent Daubert ruling, made by the Delaware Superior Court, which permits plaintiff expert testimony as part of the Zantac litigation in Delaware. GSK strongly disagrees with the Delaware Superior Court's ruling and has filed an application with the court to appeal to the Delaware Supreme Court for interlocutory review of the decision. Pfizer (PFE), Sanofi (SNY), and Boehringer Ingelheim are all parties to the application. While interlocutory reviews are granted in exceptional circumstances, GSK believes such circumstances are present here and that it is important to raise these matters now to the Delaware Supreme Court. The Superior Court's ruling is inconsistent with how the Daubert standard has been applied previously in Delaware and federal courts. As such, differing rulings interpreting how the Daubert standard is to be applied to litigation before Delaware Courts, now exist. The Superior Court's ruling would therefore have profound implications for all companies and businesses incorporated in Delaware. If the Delaware Superior Court grants the application for appeal, the case for interlocutory review of the decision will proceed to the Delaware Supreme Court for consideration. If the Delaware Superior Court rejects the application, GSK and the other defendants will seek leave to appeal directly to the Delaware Supreme Court. A decision, on whether to grant interlocutory review and hear the appeal, would be expected from the Delaware Supreme Court sometime later this year. The scientific consensus remains that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. There are 16 epidemiological studies looking at human data regarding the use of ranitidine, including outcomes for more than 1 million patients using ranitidine, supporting this consensus. GSK remains committed to vigorously defending itself and managing this litigation in the best interests of the company and its shareholders.

iatsebob Posted - 2 weeks ago

$NVAX this is the company that just partnered with $SNY right?

Grasscutter Posted - 2 weeks ago

$NVAX Sanofi wouldn’t buy in if the vaccine wasn’t already approved. $SNY

iatsebob Posted - 2 weeks ago

$NVAX $SNY knew it.

DonCorleone77 Posted - 3 weeks ago

$CRL $SNY Charles River announces launch of VCG initiative with Sanofi Charles River Laboratories (CRL) International announced the launch of its Virtual Control Groups VCG initiative with Sanofi (SNY). The companies are working together to reduce animal usage by replacing selected control group animals with selected matched virtual control animals developed using retrospective datasets. The VCG collaboration is a project guided by Charles River's Alternative Methods Advancement Project AMAP , an initiative focused on reducing the use of animals in research. "Charles River is uniquely positioned to combine the science of toxicology with the power of machine learning to drive greater use of VCGs for nonclinical research across the industry," said Shannon Parisotto, Corporate Executive Vice President, Global Discovery & Safety Assessment, Charles River. "We have an unmatched breadth of data, providing a powerful database of study parameters. By leveraging this historical information, we are able to reduce control group animals and provide clients with meaningful study results."

StockInvest_us Posted - 3 weeks ago

Signal alert: $SNY - PivotPoint bottom https://stockinvest.us/l/lD5YbQ4pTj

BixbyKnolls Posted - 3 weeks ago

@peacetrain22 They were in garbage bin till $SNY tapped them.

clan Posted - 3 weeks ago

$LLY $NVO $SNY The new Std. Of Care for mealtime insulin. Also soon the go-to for pediatric T1Ds.